During his Ph.D. training, Dr. van der Wildt developed PET tracers for in vivo imaging of active tissue transglutaminase at the department of Radiology and Nuclear Medicine at the VU University Medical Center Amsterdam, the Netherlands. He was responsible for the development of novel small molecule inhibitors, development of novel radiolabeling strategies and the in vivo evaluation of the novel PET ligands. His efforts resulted in the first tissue transglutaminase PET tracers reported to date. Following up on his Ph.D research project Berend continued working as a post-doctoral researcher at the Department of Radiology and Nuclear Medicine at the VU University Medical Center Amsterdam, where he was involved in a project that assisted a pharmaceutical company in clinical development of a tissue transglutaminase inhibitor using a PET ligand that he developed during the PhD project. Currently, Dr. van der Wildt has joined the Chin lab at Stanford University where he is responsible for chemical synthesis towards precursors and reference compounds, carbon-11 and fluorine-18 radiochemistry, and execution of preclinical imaging studies with our team.
Master of Science, Universiteit Utrecht (2012)
Doctor of Philosophy, Vrije Universiteit Amsterdam (2017)
Bachelor of Chemistry, Universiteit Utrecht (2012)